<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0001873'>Thrombocytopenia</z:hpo> is common in patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and immune destruction of platelets could be an important factor for its occurrence </plain></SENT>
<SENT sid="1" pm="."><plain>We prospectively analyzed platelet-associated IgG (PAIgG) through platelet immunofluorescence test (PIFT), mean platelet volume (MPV), platelet size deviation width (PDW) and glycocalicin index (GCI) of 54 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, classified according to the International Prognostic Scoring System (IPSS) </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0001873'>Thrombocytopenia</z:hpo> (platelet count&lt;100Ã—10(9)/L) was correlated with a higher amount of PAIgG, significantly higher MPV and increased GCI </plain></SENT>
<SENT sid="3" pm="."><plain>In addition, worse prognosis IPSS groups were associated with a higher positivity of PIFT, which could be indicative of advanced disease </plain></SENT>
</text></document>